Results 241 to 250 of about 23,218 (270)

Proprotein convertase subtilisin/kexin type 9 in human disease

2011
Cardiovascular disease (CVD) is the leading cause of death in the 21st century. Among risk factors, hypercholesterolemia and abdominal obesity are directly linked to premature development of atherosclerosis. Familial hypercholesterolemia, commonly due to low-density lipoprotein receptor (LDLR) deficiency, is known to cause premature atherosclerosis and
openaire   +1 more source

Proprotein convertase subtilisin/kexin type 9 in rheumatoid arthritis.

Clinical and experimental rheumatology, 2017
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that regulates cholesterol metabolism through low-density lipoprotein receptor degradation and that has been linked with cardiovascular risk. The purpose of the present study was to examine whether PCSK9 levels are related to both abnormalities in the lipid profile and the ...
Ivan, Ferraz-Amaro, Raquel, López-Mejías, Begoña, Ubilla, Fernanda, Genre, Beatriz, Tejera-Segura, Antonia M, de Vera-González, Agustín F, González-Rivero, Jose M, Olmos, Jose L, Hernández, Javier, Llorca, Miguel A, González-Gay   +10 more
openaire   +1 more source

Kexin

1998
Dietmar Schomburg, Dörte Stephan
openaire   +1 more source

Limulus Kexin

2013
Shun-Ichiro Kawabata, Sadaaki Iwanaga
openaire   +1 more source

Hemmung der Proproteinkonvertase Subtilisin/Kexin Typ 9

Der Diabetologe, 2018
Dirk Müller-Wieland, Julia Brandts, Nikolaus Marx, Katharina Schütt   +3 more
openaire   +1 more source

Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1

Cardiovascular Research, 2021
Ulf Landmesser, Fesc, Arash Haghikia, Lawrence A Leiter   +2 more
exaly  

Proprotein convertase subtilisin/kexin 9 (PCSK9)

Science-Business eXchange, 2008
openaire   +1 more source

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study

Lancet, The, 2012
Robert P Giugliano, Payal Kohli, Marc S Sabatine   +2 more
exaly  

Kexin

2013
openaire   +1 more source

Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia

Circulation, 2012
Frederick J Raal
exaly